


To secure capital growth from a portfolio of securities of companies engaged in Health and Pharmaceuticals and Biotechnology.
| Name | % Net Assets |
|---|---|
| PFIZER INC | 0.0% |
| ASTRAZENECA | 0.0% |
| SANOFI-AVENTIS | 0.0% |
| ABBOTT LABORATORIES | 0.0% |
| MERCK & CO INC | 0.0% |
| ROCHE HLDG AG | 0.0% |
| NOVARTIS AG | 0.0% |
| GLAXOSMITHKLINE | 0.0% |
| JOHNSON & JOHNSON | 0.0% |
| WYETH | 0.0% |
| Key | % Net Assets |
|---|---|
| 0.0% | |
| 0.0% | |
| 0.0% | |
| 0.0% | |
| 100% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 107.00p |
| Currency | GBP |
| Change | 1.10p |
| % | 1.04% |
| YTD change | -7.30p |
| YTD % | -6.39% |
| Fund Inception | 21/11/2000 |
|---|---|
| Fund Manager | Ali Toutounchi |
| TER | 1.15 (31-Dec-2013) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.00% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | -0.08 |
You are here: research